|
UPF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
4.39870362356487E-13 |
| Normal-vs-Stage3 |
8.88178419700125E-16 |
| Normal-vs-Stage4 |
1.62936331093988E-12 |
| Stage1-vs-Stage2 |
2.936200E-01 |
| Stage1-vs-Stage3 |
2.701800E-01 |
| Stage1-vs-Stage4 |
9.972400E-02 |
| Stage2-vs-Stage3 |
8.458600E-01 |
| Stage2-vs-Stage4 |
6.174600E-01 |
| Stage3-vs-Stage4 |
4.746400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.18789999999869E-05 |
| Normal-vs-Asian |
1.51040291385129E-11 |
| Caucasian-vs-AfricanAmerican |
5.092000E-02 |
| Caucasian-vs-Asian |
8.076600E-01 |
| AfricanAmerican-vs-Asian |
1.245610E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.882200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
5.08499999885004E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.547400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.929760E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.327640E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.301400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.532030E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.577400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.423600E-02 |
| Classical-VS-Follicular |
1.729810E-01 |
| Classical-VS-Other |
5.392200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
4.993200E-01 |
| Tall-VS-Other |
8.003800E-01 |
| Tall-VS-Normal |
5.11135578307176E-12 |
| Follicular-VS-Other |
8.992200E-01 |
| Follicular-VS-Normal |
1.73017156157584E-12 |
| Other-VS-Normal |
4.769100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.72306613421824E-13 |
| N0-vs-N1 |
3.607600E-01 |
|
|
